Radium-223 in real clinical practice
https://doi.org/10.33667/2078-5631-2022-5-37-41
Abstract
The first radiopharmaceutical drug for the treatment of metastatic castration-resistant prostate cancer, Radium-223, was registered in Russia in 2016. The drug has proven its effectiveness not only in reducing pain in patients with bone metastases, but also in significantly lengthening overall survival, which made it an attractive treatment option for a certain category of patients. This article presents the first results of the use of ‘Xofigo’ in the Primorsky Regional Oncological Centre.
About the Authors
A. V. Fateeva
Primorsky Cancer Centre
Russian Federation
Russian Federation
Fateeva Anastasia V., oncologist, deputy chief medical officer
Vladivostok
P. V. Statinov
Primorsky Cancer Centre
Russian Federation
Russian Federation
Statinov Pavel V., head of Dept of Radionuclide Diagnostics
Vladivostok
I. I. Kudryavtseva
Primorsky Cancer Centre
Russian Federation
Russian Federation
Kudryavtseva Irina I., methodologist
Vladivostok
E. V. Evtushenko
Primorsky Cancer Centre
Russian Federation
Russian Federation
Evtushenko Elena V., chief physician for clinical and expert work
Vladivostok
R. A. Zukov
Krasnoyarsk Regional Clinical Oncological Dispensary n. a. A. I. Kryzhanovsky
Russian Federation
Russian Federation
Zukov Ruslan A., chief physician
Krasnoyarsk
References
1. C. Parker, S. Nilsson, D. Heinrich. Alpha emitter radium‑223 and survival in metastatic prostate cancer. 2013, N Engl J Med, 369 (3): 213–23. DOI: 10.1056/NEJMoa1213755.
2. Oliver Sartor, Robert Coleman, Sten Nilsson, Daniel Heinrich. Effect of radium‑223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. 2014, Lancet Oncology, 15 (7): 738–46. DOI: 10.1016/S1470–2045(14)70183–4.
3. Matthew Smith, Chris Parker, Fred Saad, Kurt Miller. Addition of radium‑223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. 2019 Mar, Lancet Oncology, 20 (3): 408–419. DOI: 10.1016/S1470–2045(18)30860-X.
4. Neeta Pandit-Taskar, Maria Batraki, Chaitanya R Divgi.Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. 2004, Journal of Nuclear Medicine, 45 (8): 1358–65.
5. Roodman G. David. Mechanisms of Bone Metastasis. 2004, The New England Journal of Medicine, 350: 1655–1664. DOI: 10.1056/NEJMra030831.
6. C. Parker, E. Castro, K. Fizazi. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020, Annals of Oncology, DOI: https://doi.org/10.1016/j.annonc.2020.06.011
7. Kaprin, V.V. Starinsky, A.O. Shakhzodov. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: M.: MNIOI im. P.A. Gertsen – branch of NMITs Radiology, 2021. 252 p. ISBN978–5–85502–268–1.
8. O. Sartor, D. Heinrich, N. Mariados, M. J. Mendez Vidal. Re-treatment with radium‑223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. 2017, Annals of Oncology, 2464–2471. DOI: 10.1093/annonc/mdx33.
9.
Review
For citations:
Fateeva A.V., Statinov P.V., Kudryavtseva I.I., Evtushenko E.V., Zukov R.A. Radium-223 in real clinical practice. Medical alphabet. 2022;1(5):37-41. (In Russ.) https://doi.org/10.33667/2078-5631-2022-5-37-41
Views:
452
Email this article 